Article Details

Mankind Pharma Q3 FY25 PAT dips 16% to Rs. 385 Cr

Retrieved on: 2025-01-25 06:00:45

Tags for this article:

Click the tags to see associated articles and topics

Mankind Pharma Q3 FY25 PAT dips 16% to Rs. 385 Cr. View article details on hiswai:

Excerpt

... OTC business, and high-entry barrier super specialty portfolio of BSV. Mankind Pharma · pharmaceutical · Rajeev Juneja. Upcoming E-conference. Other ...

Article found on: www.indianpharmapost.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up